Generic Name and Formulations:
Yellow fever vaccine live; for SC inj; contains sorbitol, gelatin; preservative-free;.
Sanofi Pasteur, Inc.
Indications for YF-VAX:
Yellow fever immunization.
Adults and Children:
Give at least 10 days before expected exposure; may repeat every 10yrs. <9 months: not recommended. ≥9 months: 0.5mL SC.
Infants <9 months of age. Severe egg allergy (consider skin test and desensitization; see literature). Immunodeficiency or risk of immunosuppression (eg, systemic corticosteroid therapy, chemotherapy, radiation). Thymic dysfunction.
Latex allergy. Have epinephrine (1:1000) available. Elderly (increased risk of systemic events; evaluate prior to, and monitor for at least 10 days after, vaccination). Pregnancy (Cat.C). Nursing mothers.
Yellow fever vaccine.
Concomitant vaccines: see literature.
Injection site reactions, rash, headache, malaise, myalgia, fever; rare neurotropic or viscerotropic disease.
Available only to Yellow Fever Vaccination Centers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline